The Resource Intellikine : build-to-sell in biotech, Larry Lasky
Intellikine : build-to-sell in biotech, Larry Lasky
Resource Information
The item Intellikine : build-to-sell in biotech, Larry Lasky represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in University of Liverpool.This item is available to borrow from 1 library branch.
Resource Information
The item Intellikine : build-to-sell in biotech, Larry Lasky represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in University of Liverpool.
This item is available to borrow from 1 library branch.
- Summary
- The Intellikine case study provides an example of a biotech company where its management team, founders, and investors sold the company at a relatively early stage of the company's development. In early 2012, Troy Wilson, the CEO of Intellikine sold the company to Millennium: The Takeda Oncology Company, Takeda's business unit responsible for global oncology, strategy, and development. The deal was for as much as $310 million (Millennium would pay $190 million upfront, with an additional $120 million dependent on clinical development milestones). By 2011, the Intellikine team had advanced three programs into human clinical testing. The key question for students is whether Wilson and his team sold the company too early or not. Various perspectives and the company strategy and execution are provided in the case study to allow students to have a fruitful discussion on each side of the argument
- Language
- eng
- Extent
- 1 online resource.
- Note
-
- Originally published in Lasky, L. (2013). Intellikine: Build-to-sell in biotech. The Berkeley-Haas Case Series. University of California, Berkeley. Haas School of Business
- 2Teacher Notes for Sage Business Cases are available for academic staff. Contact the Liaison Librarian for Business and Management for details3
- Isbn
- 9781526409355
- Label
- Intellikine : build-to-sell in biotech
- Title
- Intellikine
- Title remainder
- build-to-sell in biotech
- Statement of responsibility
- Larry Lasky
- Language
- eng
- Summary
- The Intellikine case study provides an example of a biotech company where its management team, founders, and investors sold the company at a relatively early stage of the company's development. In early 2012, Troy Wilson, the CEO of Intellikine sold the company to Millennium: The Takeda Oncology Company, Takeda's business unit responsible for global oncology, strategy, and development. The deal was for as much as $310 million (Millennium would pay $190 million upfront, with an additional $120 million dependent on clinical development milestones). By 2011, the Intellikine team had advanced three programs into human clinical testing. The key question for students is whether Wilson and his team sold the company too early or not. Various perspectives and the company strategy and execution are provided in the case study to allow students to have a fruitful discussion on each side of the argument
- Cataloging source
- CaToSAGE
- http://library.link/vocab/creatorName
- Lasky, Larry
- Dewey number
- 658.16
- Index
- no index present
- LC call number
- HD2746.5
- LC item number
- .L37 2017
- Literary form
- non fiction
- Nature of contents
- dictionaries
- Series statement
- SAGE Knowledge. Cases
- http://library.link/vocab/subjectName
-
- Intellikine
- Consolidation and merger of corporations
- Business planning
- Biotechnology industries
- Target audience
- specialized
- Label
- Intellikine : build-to-sell in biotech, Larry Lasky
- Note
-
- Originally published in Lasky, L. (2013). Intellikine: Build-to-sell in biotech. The Berkeley-Haas Case Series. University of California, Berkeley. Haas School of Business
- 2Teacher Notes for Sage Business Cases are available for academic staff. Contact the Liaison Librarian for Business and Management for details3
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Control code
- SAGE000000686
- Extent
- 1 online resource.
- Form of item
- online
- Isbn
- 9781526409355
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Specific material designation
- remote
- Label
- Intellikine : build-to-sell in biotech, Larry Lasky
- Note
-
- Originally published in Lasky, L. (2013). Intellikine: Build-to-sell in biotech. The Berkeley-Haas Case Series. University of California, Berkeley. Haas School of Business
- 2Teacher Notes for Sage Business Cases are available for academic staff. Contact the Liaison Librarian for Business and Management for details3
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Control code
- SAGE000000686
- Extent
- 1 online resource.
- Form of item
- online
- Isbn
- 9781526409355
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Specific material designation
- remote
Library Links
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.liverpool.ac.uk/portal/Intellikine--build-to-sell-in-biotech-Larry/CV4NuYukuDE/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.liverpool.ac.uk/portal/Intellikine--build-to-sell-in-biotech-Larry/CV4NuYukuDE/">Intellikine : build-to-sell in biotech, Larry Lasky</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.liverpool.ac.uk/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.liverpool.ac.uk/">University of Liverpool</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Item Intellikine : build-to-sell in biotech, Larry Lasky
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.liverpool.ac.uk/portal/Intellikine--build-to-sell-in-biotech-Larry/CV4NuYukuDE/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.liverpool.ac.uk/portal/Intellikine--build-to-sell-in-biotech-Larry/CV4NuYukuDE/">Intellikine : build-to-sell in biotech, Larry Lasky</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.liverpool.ac.uk/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.liverpool.ac.uk/">University of Liverpool</a></span></span></span></span></div>
